Carfilzomib+Cyclophosphamide+Dexamethasone (KCd), Cyclophosphamide+Velcade+Dexamethasone (CVd), Phase 2, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), 1 prior line of therapy
### Instruction:
Identify the study with the following condition. 
### Input:
Carfilzomib+Cyclophosphamide+Dexamethasone (KCd), Cyclophosphamide+Velcade+Dexamethasone (CVd), Phase 2, Proteasome Inhibitors (PI), Relapsed Refractory Multiple Myeloma (RRMM), 1 prior line of therapy 
### Output:
Popular Name is MUK Five, Study ID is ISRCTN17354232